Review of 8 years of experience with Infanrix hexa™ (DTPa-HBV-IPV/Hib hexavalent vaccine)

Expert Review of Vaccines

Volumn 8, Issue 6, 2009, Pages 663-678

  Zepp, Fred ^a   Schmitt, Heinz Josef ^b   Cleerbout, Jan ^c   Verstraeten, Thomas ^c   Schuerman, Lode ^c   Jacquet, Jeanne Marie ^c  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Novartis Vaccine   (Germany)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Combination; Haemophilus influenzae type b; Hepatitis b; Hexavalent; Immunogenicity; Infanrix hexa ; Pertussis; Safety; Vaccination

Indexed keywords

CHICKENPOX MEASLES MUMPS RUBELLA VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; PRIORIX TETRA; ROTAVIRUS VACCINE; UNCLASSIFIED DRUG;

CRYING; DIPHTHERIA; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEVER; HAEMOPHILUS INFECTION; HEPATITIS B; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE REACTION; INJECTION SITE SWELLING; IRRITABILITY; MUSCLE HYPOTONIA; PAIN; PALLOR; PERTUSSIS; POLIOMYELITIS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SUDDEN DEATH; SWELLING; TETANUS; URTICARIA;

CLINICAL TRIALS AS TOPIC; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; HAEMOPHILUS VACCINES; HUMANS; POLIOVIRUS VACCINE, INACTIVATED; PRODUCT SURVEILLANCE, POSTMARKETING; VACCINES, COMBINED;

EID: 67249141494     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.09.32     Document Type: Review

References (89)

1. Atkinson WL, Pickering LK, Schwartz B et al. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices and the American Academy of Family Physicians. Morbid. Mortal. Wkly Rep. 51(RR-2), 1-34 (2002).
2. Mullany L. Considerations for implementing a new combination vaccine into managed care. Am. J. Manag. Care 9, 23-29 (2003). (Pubitemid 36192809)
3. Schmitt HJ, Booy R, Weil-Olivier C, Van Damme P, Cohen R, Peltola H. Child vaccination policies in Europe: a report from the Summits of Independent European vaccination Experts. Lancet Infect. Dis. 3, 103-108 (2003). (Pubitemid 36167813)
4. Expanded Programme on Immunization. Global Advisory Group Part I. Wkly Epidemiol. Rec. 67 (1992).
5. Van Damme P, Kane M, Meheus A. Integration of hepatitis B vaccination into national immunisation programmes. Viral Hepatitis Prevention Board. BMJ 5, 1033-1036 (1997).
6. GlaxoSmithKline Biologicals, Rixensart, Belgium. Infanrix hexa™ European Summary of Product Characteristics. 17 November 2005.
7. Safary A, André FE. Clinical experience with a yeast-derived hepatitis B vaccine. J. Chemother. 1, 1096-1098 (1989).
8. André FE. Development and clinical application of new polyvalent combined pediatric vaccines. Vaccine 17, 1620-1627 (1999).
9. Edwards KM, Decker MD. Pertussis vaccines. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA, Offit PA (Eds). Saunders, PA, USA, 467-517 (2008).
10. Schmitt HJ, Knuf M, Ortiz E, Sänger R, Uwamwezi MC, Kaufhold A. Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections. J. Pediatr. 137, 304-312 (2000).
11. Avdicová M, Prikazský V, Hudecková H et al. Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV/Hib vaccine compared with separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule. Eur. J. Pediatr. 161, 581-587 (2002). (Pubitemid 35471811)
12. Pichichero ME, Blatter MM, Reisinger KS et al. Impact of a birth dose of hepatitis B vaccine on the reactogenicity and immunogenicity of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b combination vaccination. Pediatr. Infect. Dis. J. 21, 854-859 (2002).
13. Arístegui J, Dal-Ré R, Díez-Delgado J et al. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age. Vaccine 21, 3593-3600 (2003).
14. Gabutti G, Zepp F, Schuerman L et al. Evaluation of the immunogenicity and reactogenicity of a DTPa-HBV-IPV combination vaccine co-administered with a Hib conjugate vaccine either as a single injection of a hexavalent combination or as two separate injections as 3, 5 and 11 months of age. Scand. J. Infect. Dis. 36, 585-1392 (2004). (Pubitemid 39255358)
15. Nolan T, Altmann A, Skeljo M, Streeton C, Schuerman L. Antibody persistence, PRP-specific immune memory, and booster responses in infants immunised with a combination DTPa-HBV-IPV/Hib vaccine. Vaccine 23, 14-20 (2004). • Shows that primary vaccination with diphtheria, tetanus, acellular pertussis-hepatitis B virus-inactivated poliovirus vaccine/Haemophilus influenzae type b vaccine (DTPA-HBV-IPV/Hib) in infants induces Hib-specific immune memory in the second year of life.
16. Tejedor JC, Omeñaca F, García-Sicilia J et al. Immunogenicity and reactogenicity of a three-dose primary vaccination course with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine coadministered with a meningococcal C conjugate vaccine. Pediatr. Infect. Dis. J. 23, 1109-1115 (2004). (Pubitemid 40812757)
17. Zepp F, Knuf M, Heininger U et al. Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants. Vaccine 22, 2226-2233 (2004). (Pubitemid 38626062)
18. Black S, Nakasato C, Davis R et al. Two large Phase III, multicenter trials comparing primary vaccination with DTPa-HBV-IPV/Hib versus commercially available vaccines administered at separate sites. Presented at: 4th World Congress of the World Society for Pediatric Infectious Diseases (WSPID). Warsaw, Poland, 1-4 September 2005.
19. Omeñaca F, Garcia-Sicilia J, García-Corbeira P et al. Response of preterm newborns to immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio and Haemophilus influenzae type b vaccine: first experiences and solutions to a serious and sensitive issue. Pediatrics 116, 1292-1298 (2005). • Shows DTPa-HBV-IPV/Hib to be immunogenic and well tolerated in infants born prematurely. (Pubitemid 46056474)
20. Tichmann I, Preidel H, Grunert D et al. Comparison of the immunogenicity and reactogenicity of two commercially available hexavalent vaccines administered as a primary vaccination course at 2, 4 and 6 months of age. Vaccine 23, 3272-3279 (2005). (Pubitemid 40523120)
21. Tichmann-Schumann I, Soemantri P, Behre U et al. Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-component acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccine co-administered with 7-valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 24, 70-77 (2005). (Pubitemid 40353319)
22. Knuf M, Habermehl P, Cimino C, Petersen G, Schmitt HJ. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants. Vaccine 24, 4727-4736 (2006). (Pubitemid 43776787)
23. Tejedor JC, Moro M, Ruiz-Contreras J et al. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus- acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine. Pediatr. Infect. Dis. J. 25, 713-720 (2006). (Pubitemid 44162129)
24. Tichmann I, Grunert D, Habash S et al. Persistence of antibodies in children primed with two different hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccines and evaluation of booster vaccination. Hum. Vaccin. 2, 249-254 (2006). (Pubitemid 46025656)
25. Gatchalian S, Bravo L, Cadorna-Carlos J et al. A hexavalent DTPa-HBV-IPV/Hib vaccine administered to Filipino infants at 6, 10 and 14 weeks and at 12-15 months of age, with or without a birth dose of HBV. Presented at: 12th Asia Pacific Congress of Pediatrics (APCP). Columbo, Sri Lanka, 5-9 September 2007.
26. Heininger U; DTP-HBV-IPV-059 Study Group; DTP-HBV-IPV-096 Study Group, Sänger R, Jacquet JM, Schuerman L. Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses. Vaccine 25, 1055-1063 (2007). •• Pivotal follow-up study demonstrating that seroprotective antibody levels persist in children at least 3.5-4 years after full immunization with Infanrix hexa™.
27. Omeñaca F, Garcia-Sicilia J, García-Corbeira P, Boceta R, Torres V. Antipolyribosyl ribitol phosphate response of premature infants to primary and booster vaccination with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus/Haemophilus influenzae type b vaccine. Pediatrics 119, e179-e185 (2007). (Pubitemid 46397823)
28. Zepp F, Behre U, Kindler K et al. Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine co-administered with a booster dose of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in healthy children aged 12-23 months. Eur. J. Pediatr. 166, 857-864 (2007). (Pubitemid 46988187)
29. Kilpi T, Silfverdal SA, Nilsson L et al. Immunogenicity and reactogenicity of two diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccines administered at 3, 5 and 11-12 months of age. Hum. Vaccin. 5, 18-25 (2009).
30. Zinke M, Kappes R, Kindler K et al. Immune memory against hepatitis B persists in 7-9 year olds previously vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine. Presented at : 26th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID). Graz, Austria, 13-17 May 2008 (Abstract 629). •• Demonstrates that DTPa-HBV-IPV/Hib induces sustained seroprotection against hepatitis B up to 6.5 years after the last vaccine dose; challenge indicates but also induces immune memory (as shown by a strong response to a subsequent HBV dose).
31. Zinke M, Disselhoff J, the DTPa-HBV-IPV-110 and -111 study groups, Gartner B, Jacquet JM. Immunological persistence in 4-6 and 7-9 year olds previously vaccinated in infancy with hexavalent DTPa-HBV-IPV/Hib. Presented at: The 26th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID). Graz, Austria, 13-17 May 2008 (Abstract 628).
32. WHO. Hepatitis B vaccines. WHO position paper. Wkly Epidemiol. Rec. 79, 253-264 (2004).
33. Mansoor OD, Salama P. Should hepatitis B vaccine be used for infants? Expert Rev. Vaccines 6(1), 29-33 (2007). (Pubitemid 46232478)
34. Mast E, Mahony F, Kane M, Margolis H. Hepatitis B vaccine. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA, Offit PA (Eds). Saunders, PA, USA, 205-241 (2008).
35. Van Herck K, Van Damme P. Benefits of early hepatitis B immunization programs for newborns and infants. Pediatr. Infect. Dis. J. 27, 861-869 (2008).
36. Zanetti A, Mariano A, Romanò L et al. Long-term immunogenicity of hepatitis B vaccinations and policy for booster: an Italian multicentre study. Lancet 366, 1379-1384 (2005). (Pubitemid 41443405)
37. Da Villa G, Romanò L, Sepe A et al. Impact of hepatitis B vaccination in a highly endemic area of south Italy and long-term duration of anti-HBs antibody in two cohorts of vaccinated individuals. Vaccine 25, 3133-3136 (2007). (Pubitemid 46482751)
38. McIntyre P. Invasive Haemophilus influenzae type b disease in Australia: the beginning of the end? Med. J. Aust. 156. 516-518 (1992).
39. Harris A, Hendrie D, Bower C, Payne J, de Klerk N, Stanley F. The burden of Haemophilus influenzae type b disease in Australia and an economic appraisal of the vaccine PRP-OMP. Med. J. Aust. 160, 483-488 (1994). (Pubitemid 24140984)
40. Garpenholt O, Silfverdal SA, Hugosson S et al. The impact of Haemophilus influenzae type b vaccination in Sweden. Scand. J. Infect. Dis. 28, 165-169 (1996). (Pubitemid 26169488)
41. Chandran A, Watt JP, Santosham M. Haemophilus influenzae vaccines. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA, Offit PA (Eds). Saunders, PA, USA 157-176 (2008).
42. Schmitt HJ. Immunogenicity and reactogenicity of two Haemophilus influenzae type b tetanus conjugate vaccines administered by reconstituting with diphtheria-tetanus-acellular pertussis vaccine or given as separate injections. Presented at: 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA, USA 17-20 September 1995.
43. Eskola J, Olander RM, Hovi T, Litmanen L, Peltola S, Käyhty H. Randomised trial of the effect of coadministration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Lancet 348, 1688-1692 (1996). (Pubitemid 27007531)
44. Eskola J, Ward J, Dagan R, Goldblatt D, Zepp F, Siegrist CA. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus- pertussis containing acellular pertussis. Lancet 354, 2063-2068 (1999).
45. Dagan R, Poolman JT, Zepp F. Combination vaccine containing DTPa-Hib: impact of IPV and coadministration of CRM197 conjugates. Expert Rev. Vaccines 7(1), 97-115 (2008).
46. Decker MD. Edwards KM, Bogaerts HH. Combination vaccines. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA, Offit PA (Eds). Saunders, PA, USA, 1069-1101 (2008).
47. Zepp F, Schmitt HJ, Kaufhold A et al. Evidence for induction of polysaccharide specific B-cell-memory in the 1st year of life: plain Haemophilus influenzae type b-PRP (Hib) boosters children primed with a tetanus-conjugate Hib-DTPa-HBV combined vaccine. Eur. J. Pediatr. 156, 18-24 (1997). (Pubitemid 26425772)
48. Kalies H, Verstraeten T, Grote V et al. Four and one-half-year follow-up of the effectiveness of diphtheria-tetanus toxoids-acellular pertussis/Haemophilus influenzae type b and diphtheria-tetanus toxoids-acellular pertussis-inactivated poliovirus/H. influenzae type b combination vaccines in Germany. Pediatr. Infect. Dis. J. 23, 944-950 (2004). (Pubitemid 40812782)
49. Kalies H, Groendahl B, Schmitt HJ, Siedler A, von Kries R. Effectiveness of hexavalent vaccines against invasive haemophilus influenzae type b disease in Germany. Presented at: 23rd Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID). Valencia, Spain, 18-20 May 2005.
50. Kalies H, Grote V, Siedler A, Gröndahl B, Schmitt HJ, von Kries R. Effectiveness of hexavalent vaccines against invasive Haemophilus influenzae type b disease: Germany's experience after 5 years of licensure. Vaccine 26, 2545-2552 (2008). •• Landmark 5-year postmarketing surveillance study demonstrating the major impact hexavalent vaccines have had on the incidence of invasive Hib disease in Germany since their introduction.
51. Ramsay ME, McVernon J, Andrews NJ, Heath PT, Slack MP. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J. Infect. Dis. 188, 481-485 (2003). (Pubitemid 37011798)
52. Fitzgerald M, Canny M, O'Flanagan D. Vaccination catch-up campaign in response to recent increase in Hib infection in Ireland. Euro Surveill. 10(9), E050929.2 (2005).
53. Steinhoff M, Goldblatt D. Conjugate Hib vaccines. Lancet 361, 360-361 (2003). (Pubitemid 36164964)
54. Denoël PA, Goldblatt D, de Vleeschauwer I, Jacquet JM, Pichichero ME, Poolman JT. Quality of the Haemophilus influenzae type b (Hib) antibody response induced by diphtheria-tetanus-acellular pertussis/Hib combination vaccines. Clin. Vaccine Immunol. 14, 1362-1369 (2007). (Pubitemid 350012980)
55. Cohen R, Schuerman L. Reactogenicity of a new DTPa-HBV-IPV (+ & /Hib) vaccines after primary and booster doses. Presented at: 18th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID). Noordwijk, The Netherlands, 3-5 May 2000.
56. Saenger R, Maechler G, Potreck M et al. Booster vaccination with hexavalent DTPa-HBV-IPV/Hib vaccine in the second year of life is as safe as concomitant DTPa-IPV/Hib + HBV administered separately. Vaccine 23, 1135-1143 (2005). (Pubitemid 40063547)
57. Rennels MB, Deloria MA, Pichichero ME et al. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. Pediatrics 105, e12 (2000).
58. Schmitt HJ, Beutel K, Schuind A et al. Reactogenicity and immunogenicity of a booster dose of a combined diphtheria, tetanus, and tricomponent acellular pertussis vaccine at fourteen to twenty-eight months of age. J. Pediatr. 130, 616-623 (1997). (Pubitemid 27492654)
59. Saari TN; American Academy of Pediatrics Committee on Infectious Diseases. Immunization of preterm and low birth weight infants. American Academy of Pediatrics Committee on Infectious Diseases. Pediatrics 112, 193-198 (2003).
60. Kroger AT, Atkinson WL, Marcuse EK, Pickering LK; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid. Mortal. Wkly Recomm. Rep. 55(RR-15), 1-48 (2006).
61. Baraff LJ, Ablon WJ, Weiss RC. Possible temporal association between diphtheria-tetanus toxoid-pertussis vaccination and sudden infant death syndrome. Pediatr. Infect. Dis. 2, 7-11 (1983).
62. Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin. Microbiol. Rev. 18, 326-382 (2005). (Pubitemid 40548297)
63. Hoffman, HJ, Hunter JC, Damus K et al. Diphtheria-tetanus-pertussis immunization and sudden infant death: results of the National Institute of Child Health and Human Development Cooperative Epidemiological Study of Sudden Infant Death Syndrome risk factors. Pediatrics 79, 598-611 (1987). (Pubitemid 17051428)
64. Griffin MR, Ray WA, Livengood JR, Schaffner W. Risk of sudden infant death syndrome after immunization with the diphtheria-tetanus-pertussis vaccine. N. Engl. J. Med. 319, 618-623 (1988). (Pubitemid 18209712)
65. Keller-Stanislawski B, Löwer J. Todesfälle in zeitlichem Zusammenhang mit Sechsfachimpfung. Kinder und Jugendarzt 34, 608-613 (2003).
66. von Kries R, Toschke AM, Straßburger K et al. Sudden and unexpected deaths after the administration of hexavalent vaccines (diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, Haemophilius influenzae type b): is there a signal? Eur. J. Pediatr. 164, 61-69 (2005). (Pubitemid 40311565)
67. von Kries R. Comment on B. Zinka et al. Unexplained cases of sudden infant death shortly after hexavalent vaccination. Vaccine 24, 5783-5784 (2006). (Pubitemid 43947384)
68. Vennemann MM, Höffgen M, Bajanowski T, Hense HW, Mitchell EA. Do immunisations reduce the risk for SIDS? A meta-ana lysis. Vaccine 25, 4875-4879 (2007). (Pubitemid 46843431)
69. Meyerhoff AS, Greenberg DP, Jacobs RJ. Predicted effects of a new combination vaccine on childhood immunization coverage rates and vaccination activities. Dis. Manage. Health Outcomes 13, 317-326 (2005). (Pubitemid 41381466)
70. Kalies H, Grote V, Verstraeten T, Hessel L, Schmitt HJ, von Kries R. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr. Infect. Dis. J. 25, 507-512 (2006). • Demonstrates how hexavalent vaccines have shortened the delay in children receiving their scheduled vaccine doses, optimizing the period of protection in the most vulnerable. (Pubitemid 43863360)
71. Marshall GS, Happe LE, Lunacsek OE et al. Use of combination vaccines is associated with improved coverage rates. Pediatr. Infect. Dis. J. 26, 496-500 (2007). (Pubitemid 46847310)
72. Tozzi AE, Azzari C, Bartolozzi G, Esposito S, Fara GM, Giudice ML. Can hexavalent vaccines be simultaneously administered with pneumococcal and meningococcal conjugate vaccines? Hum. Vaccin. 3, 252-259 (2007). • Review of four papers demonstrating that coadministration of Infanrix hexa with pneumococcal or meningococcal vaccines has no noteworthy effect on their immunogenicity or tolerability profiles.
73. Schmitt HJ, Habermehl P, Knuf M, Ypma E, Borkowski A. Safety, reactogenicity and immunogenicity/priming following 2 vs. 3 doses of a meningococcal C conjugate vaccine (MCC) given concomitantly with DTaP-IPV-HBV/Hib vaccine to infants. Presented at: 23rd Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID). Valencia, Spain, 18-20 May 2005.
74. Schmitt HJ, Maechler G, Habermehl P et al. Immunogenicity, reactogenicity, and immune memory after primary vaccination with a novel Haemophilus influenzae-Neisseria meningitidis serogroup C conjugate vaccine. Clin. Vaccine Immunol. 14, 426-434 (2007). (Pubitemid 46732554)
75. Vesikari T, Prymula R, Schuster V et al. Rotarix™ (RIX4414), an oral human rotavirus vaccine, is highly immunogenic when co-administered with diphtheria-tetanus-pertusis(DTPa)-combined vaccines in healthy infants from Europe. Presented at: 24th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID). Basel, Switzerland, 3-5 May 2006.
76. Zepp F. 'My Generation' - an international study investigating mothers' concerns about vaccination: analysis of initial findings. Presented at: 4th Congress of the World Society for Pediatric Infectious Diseases (WSPID). Warsaw, Poland 1-4 September 2005 (Abstract G-915).
77. Offit PA, Quarles J, Gerber MA et al. Addressing parents' concerns: do multiple vaccines overwhelm or weaken the infant's immune system? Pediatrics 109, 124-129 (2002). (Pubitemid 34049436)
78. Schmitt HJ, Booy R, Aston R et al. How to optimise the coverage rate of infant and adult immunisations in Europe. BMC Med. 5, 11 (2007). (Pubitemid 47038980)
79. WHO. 2005. Global Advisory Committee on Vaccine Safety, 9-10 June 2005. Wkly Epidemiol. Rec. 80, 242-247 (2005).
80. Scott DA, Komjathy SF, Hu BT et al. Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. Vaccine 25, 6164-6166 (2007). (Pubitemid 47088041)
81. EUVAC.NET. National childhood vaccination schedules www.euvac.net/ graphics/euvac/vaccination/vaccination.html (Accessed September 2008)
82. WHO. Vaccine Preventable Diseases Monitoring System. 2007 Global summary www.who.int/vaccines/globalsummary/immunization/countryprofileselect.cfm (Accessed September 2008)
83. WHO. Fact sheet No.204 (revised August 2008). Hepatitis B www.who.int/mediacentre/factsheets/fs204/en/print.html (Accessed September 2008)
84. WHO 2008. Hepatitis B www.who.int/immunization-monitoring/diseases/ hepatitis/en/ (Accessed September 2008)
85. European Agency for the Evaluation of Medicinal Products (EMEA). Press release. European Medicines Agency recommends suspension of Hexavac. (2005) www.emea.europa.eu/humandiocs/pdfs/epar/hexavac/29736905en.pdf (Accessed September 2008)
86. WHO. Haemophilus influenzae type b (Hib) www.who.int/mediacentre/ factsheets/fs294/en/index.html (Accessed September 2008)
87. European Agency for the Evaluation of Medicinal Products (EMEA). Procedural steps taken and scientific information after the authorization: changes made after 01/11/2002 (Infanrix hexa) (2008) www.emea.europa.eu/ humandocs/pdfs/epar/infanrixhexa/200500en8b.pdf (Accessed September 2008)
88. European Agency for the Evaluation of Medicinal Products (EMEA). Public statement. EMEA reviews hexavalent vaccines: Hexavac and Infanrix hexa. (2003) www.emea.europa.eu/pdfs/human/press/pus/851903en.pdf (Accessed September 2008)
89. European Agency for the Evaluation of Medicinal Products (EMEA). Public statement. EMEA update on hexavalent vaccines: Hexavac and Infanrix hexa. (2003) www.emea.europa.eu/pdfs/human/press/pus/588903en.pdf (Accessed September 2008)